Drug Profile
Research programme: rare genetic disorder therapeutics - Takeda Pharmaceutical/Ultragenyx Pharmaceutical
Latest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator Takeda
- Developer Takeda; Ultragenyx Pharmaceutical
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for research development in Unspecified in USA
- 07 Jun 2016 Takeda Pharmaceutical and Ultragenyx Pharmaceutical agree to co-develop and co-commercialise drug candidates for rare genetic disorders
- 07 Jun 2016 Early research in Undefined indication in USA